Zwisler Laboratorium was founded in 2001 and operates a modern laboratory in southern Germany. The company provides specialized services for the pharmaceutical, biotechnology, packaging and medical device industries throughout Europe. The laboratory specializes in in-vitro pyrogen testing, IFU (instructions for use), reprocessing validation, environmental monitoring, microbiological integrity testing and individual consulting services to help customers meet stringent regulatory requirements. The company has also developed innovative in-vitro testing methods to reduce in-vivo testing and further expand its innovative capabilities.
Cormica is a global leader in life sciences testing and consulting services and is backed by UK private equity investment firm Limerston Capital. The company operates state-of-the-art laboratory facilities in the UK and the US and offers a wide range of testing services. These include feasibility studies for medical devices, in-vitro validation, stability studies for pharmaceuticals and medical devices and batch release testing. In addition, the service portfolio includes GxP compliance, biocompatibility testing, sterility testing, microbiological testing and physical performance testing.
As a fast-growing global player, Cormica is committed to helping life science manufacturers bring life-saving medical technologies to market faster, safer and more efficiently.
The acquisition of Zwisler Laboratorium adds microbiology expertise from Germany to Cormica's service offering. This enables customers to benefit from an expanded range of services. At the same time, Cormica strengthens its ability to support clients in addressing complex regulatory requirements in Europe and beyond.
Limerston Capital was founded in London in 2015 by James Paget, João Rosa and Martim Avillez and focuses on majority investments in UK mid-market companies. The investment company pursues a buy-and-build strategy with an operational focus. It invests in companies with an EBITDA of between GBP 5 and 15 million that have a solid business model but show potential for operational improvement, strategic repositioning or consolidation.
Limerston Capital supports Cormica's growth and expansion into the European market. The acquisition of Zwisler Laboratorium marks an important milestone for Cormica as it facilitates market entry in Germany and further strengthens the company's growth trajectory in Europe.
ConAlliance is a global leading M&A advisory firms in the healthcare sector and provides comprehensive support to companies in acquisition and sales processes. Since its foundation, the company has successfully advised over 250 transactions.
ConAlliance's industry expertise is highly specialized and focuses exclusively on company acquisitions and sales in the global healthcare and life sciences industry. To this end, ConAlliance has put together specialized teams which, in addition to classic investment banking know-how, have in-depth expertise in the respective healthcare niches.
Thanks to the comprehensive expertise of the ConAlliance team, particularly in the laboratory segment, it was possible to provide advice throughout the entire transaction process and to initiate and support the successful implementation of the acquisition.
ConAlliance advised Limerston Capital on the buy-and-build strategy, initiated the transaction and advised on the acquisition. The parties have agreed not to disclose the details of the transaction.
Head of the ConAlliance team in this transaction: Günter Carl Hober, Managing Partner supported by Alexander Mast and Martin E. Franz as partners on behalf of ConAlliance.